| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2018: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Outline of Final Research Achievements |
Using claims data and econometric methods, the following results were obtained. (1) Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditures among high-income group. (2) Both inertia and heterogeneity in brand preferences have substantial effects on the choice of brand-name pitavastatin or generic ones. Counterfactual simulations suggest that a nudging policy that removes inertia from previous brand-name users may have substantial effects and enable patients to choose optimally. (3) Regarding the impacts of medical subsidy for children, no significant effect of the stop-loss policy on health services expenditures was observed, while the free prescription policy significantly increased prescription drug expenditures among children with relatively good health status. The stop-loss policy for children is potentially efficient in terms of the policy of medical subsidy for children.
|
